Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer Aggressiveness”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02437539
What this trial is testing

Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

Who this might be right for
Breast CancerProstate CancerUrinary Bladder Cancer
Rigshospitalet, Denmark 10
Not applicableUnknownNCT04283032
What this trial is testing

Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis

Who this might be right for
Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason ClassificationEstablish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the TechniqueEstablish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life+4 more
InvestigatorUrologyIBSAL
Testing effectiveness (Phase 2)Active Not RecruitingNCT04709276
What this trial is testing

Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Cancer
Andrew J. Armstrong, MD 41
Not applicableNot Yet RecruitingNCT06662708
What this trial is testing

Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer

Who this might be right for
Prostate CancerProstate Intraductal CarcinomaProstate Cancer Aggressiveness+2 more
Shao Pengfei 200
Not applicableStudy completedNCT05384002
What this trial is testing

An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum

Who this might be right for
Prostate CancerProstate Cancer MetastaticProstate Cancer Recurrent+1 more
Fondazione del Piemonte per l'Oncologia 14,000
Very early researchUnknownNCT03960788
What this trial is testing

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Who this might be right for
Cancer of the ProstateCastration-resistant Prostate Cancer
University of Cincinnati 50
Not applicableStudy completedNCT03289130
What this trial is testing

Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness

Who this might be right for
Prostatic Neoplasm
University of South Carolina 2,258
Testing effectiveness (Phase 2)UnknownNCT03307460
What this trial is testing

UPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

Who this might be right for
Prostate Cancer
Rigshospitalet, Denmark 52
Testing effectiveness (Phase 2)Looking for participantsNCT06085729
What this trial is testing

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT07218666
What this trial is testing

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

Who this might be right for
Aggressive Variant Prostate Carcinoma
Deepak Kilari 30
Not applicableActive Not RecruitingNCT02095249
What this trial is testing

Prostate Hypoxia - TIC

Who this might be right for
Prostate Cancer
University Health Network, Toronto 39
Not applicableLooking for participantsNCT04472338
What this trial is testing

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Who this might be right for
Prostate Carcinoma
University of Washington 450
Not applicableStudy completedNCT01780701
What this trial is testing

Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

Who this might be right for
Prostate Cancer
OHSU Knight Cancer Institute 66
Not applicableStudy completedNCT02689271
What this trial is testing

CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr

Who this might be right for
Prostate Cancer
University College, London 365
Not applicableStudy completedNCT01347476
What this trial is testing

Aggressive Prostate Cancers in Elderly Patients

Who this might be right for
Prostatic Neoplasms
Seoul National University Hospital 1,333
Not applicableStudy completedNCT03232411
What this trial is testing

Biobank for African American Prostate Cancer Research in Florida

Who this might be right for
Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 592
Not applicableLooking for participantsNCT05539677
What this trial is testing

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Who this might be right for
Malignant Solid TumorsPrimary Brain TumorMelanoma+4 more
N.N. Petrov National Medical Research Center of Oncology 1,000
Not applicableEnded earlyNCT03256630
What this trial is testing

Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Who this might be right for
Prostate Cancer
Genomic Health®, Inc. 128
Not applicableStudy completedNCT02076503
What this trial is testing

Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status

Who this might be right for
Prostatic Neoplasms
St. Olavs Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Next Page
628